Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making

INTRODUCTION: Reclassification of HER2-negative breast cancers to HER2 low-level expression allowed targeted anti-HER2 therapy in about 60% of patients, improving outcome. The high recurrence rates and often dismal outcomes with current therapies of high-grade Mullerian carcinomas, offers opportunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Abada, Evi, Singh, Kamaljeet, Hansen, Katrine, Quddus, M. Ruhul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432814/
https://www.ncbi.nlm.nih.gov/pubmed/37600081
http://dx.doi.org/10.1016/j.gore.2023.101251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432814/
https://www.ncbi.nlm.nih.gov/pubmed/37600081
http://dx.doi.org/10.1016/j.gore.2023.101251

Ejemplares similares